Table of Contents Table of Contents
Previous Page  280 / 280
Information
Show Menu
Previous Page 280 / 280
Page Background

The Buckingham Institute of

Translational Medicine

The Buckingham Institute of Translational Medicine is based within the Clore Laboratory

and is an internationally recognised preclinical research group in the area of diabetes and

obesity research. It has staff with nearly 150 man-years’ pharmaceutical industry

experience. It is led by Professor Mike Cawthorne, who was awarded the 2001 Society of

Medicines Award for drug discovery in recognition of his work on the discovery of the

insulin sensitiser drug rosiglitazone. All with their own historical areas of interest, the

team also includes Jon Arch (ß

3

-adrenoceptor agonists, orexin and MCH-antagonists –

formerly at GSK), John Clapham (insulin sensitisers, ucp-3, thermogenesis – formerly GSK

and AZ) and Paul Finn (chemoinformatics, molecular modelling – formerly InhibOx).

Academic members of the research team and their specialities include Paul Trayhurn

(brown and white adipose tissue metabolism), Claire Stocker (metabolic programming

and chemerin), Kenneth Langlands (cancer and skin biology, bioinformatics and

bioimaging), Ed Wargent (

in vivo

pharmacology, cannabinoids and plant extracts),

Mohamed Zaibi (

in vivo

pharmacology, cannabinoids and plant extracts), Joanne Selway

(cancer and skin biology and bioimaging), Maysson Al-Ibrahim (bioinformatics and

pathway analysis) and Jacqueline O’Dowd (islet cell metabolism).

The research focus of the institute covers two principal areas – metabolic diseases

(including obesity, diabetes, cardiovascular disease and Alzheimer’s) and dermatology.

The research programmes range from

in silico

through cell culture and

in vitro

biology to

in vivo

studies followed by phenotypic and analyte analysis, cellular studies,

immunohistochemistry imaging, and transcriptomic and pathway analysis. The core

competence is

in vivo

physiology of metabolic disease and the predictability of animal

model systems with therapeutic efficacy in man. Such studies are designed to inform

drug discovery and development and enhance biological understanding.

The research group has collaborations with many academic laboratories and

pharmaceutical and biotech companies. It welcomes further collaborations to develop

pioneering molecules and establish potential therapeutic benefits. It has a particular

interest in developing plant-based medicines with measurable therapeutic efficacy to be

used as either preventatives or treatment of metabolic disease.

Clore Laboratory

University of Buckingham

tel: +44 (0)1280 820309

mike.cawthorne@buckingham.ac.uk www.buckingham.ac.uk/clore